Total hip replacement and antithrombotic prophylaxis.

I J Brenkel; M J Clancy

Home/Archive/PubMed

PubMed · 2636867

Total hip replacement and antithrombotic prophylaxis.

I J Brenkel·M J Clancy

View original source ↗Export metadata ↓

Abstract

British orthopaedic surgeons were surveyed to assess the practice of prophylaxis against thromboembolism in patients undergoing total hip replacements. Of 690 surgeons, 348 (50.4%) do not routinely use pharmacological prophylaxis (190 use no prophylaxis while 158 use a mechanical form of prophylaxis), 289 (41.9%) surgeons use a single pharmacological agent (with or without a mechanical form of prophylaxis), and the remaining 53 (7.7%) use two or more pharmacological agents.

Explore related subjects

Antithrombins Hip Prosthesis Humans Postoperative Complications Surveys and Questionnaires Thromboembolism United Kingdom Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

I J Brenkel, M J Clancy. 1989. Total hip replacement and antithrombotic prophylaxis.. https://pubmed.ncbi.nlm.nih.gov/2636867/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Detecting antithrombin deficiency may be a difficult task--more than one test is necessary.

Explore the source record for details and available documents.

Antithrombins↗

PubMed2006

Analysis of inhibition rate enhancement by covalent linkage of antithrombin to heparin as a potential predictor of reaction mechanism.

Antithrombin (AT) inhibition of coagulation enzymes is catalyzed by unfractionated heparin (UFH) and other heparinoids. Reaction proceeds either via conformational activation of the inhibitor or template-mediated binding of both inhibitor and protease. We investigated if the relative inhibition rates of AT + UFH and covalent AT-heparin conjugate (ATH) with coagulation factors might be indicative of the mechanism involved. Rates were determined by discontinuous assay and mechanisms were probed by a variety of binding studies with UFH or ATH heparin chains. Rates were increased more than 2-fold with ATH over AT + UFH in reactions with thrombin, factor (F) VIIa + tissue factor + Ca2+ + lipid, FIXa and FXIa, but not with FXa or FXIIa. In comparison, UFH or ATH heparin binding (evidence of a template mechanism) was only observed with thrombin, tissue factor, FIXa and FXIa. Thus, inhibition rate enhancement by conjugation of AT with heparin were predictive of inhibitor.enzyme template bridging by heparin. Rationales behind this novel concept are discussed.

Antithrombins↗

PubMed2006

{4(S)-(Piperidin-1-ylcarbonyl)-4-[3-(trifluoromethyl)phenylsulfonamido]butyl}guanidinium chloride: a model of a graftable thrombin inhibitor.

In the title compound, C18H27F3N5O3S+.Cl-, the guanidine group forms N-H...Cl hydrogen bonds, with four N...Cl distances in the range 3.164 (3)-3.337 (4) A. In the crystal packing, the cations are further linked by N-H...O and C-H...O interactions. The structure is compared with that of argatroban complexed with thrombin and is the subject of docking studies in the active site of thrombin.

Antithrombins↗